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Summary
Background: The target of rapamycin (TOR), in com-
plex with the proteins raptor and LST8 (TOR complex
1), phosphorylates the p70S6K and 4E-BP1 to promote
mRNA translation. Genetic evidence establishes that
TOR complex activity in vivo requires the small GTPase
Rheb, and overexpression of Rheb can rescue TOR
from inactivation in vivo by amino-acid withdrawal. The
Tuberous Sclerosis heterodimer (TSC1/TSC2) functions
as a Rheb GTPase activator and inhibits TOR signaling
in vivo.
Results: Here, we show that Rheb binds to the TOR
complex specifically, independently of its ability to bind
TSC2, through separate interactions with the mTOR cat-
alytic domain and with LST8. Rheb binding to the TOR
complex in vivo and in vitro does not require Rheb gua-
nyl nucleotide charging but is modulated by GTP and
impaired by certain mutations (Ile39Lys) in the switch 1
loop. Nucleotide-deficient Rheb mutants, although ca-
pable of binding mTOR in vivo and in vitro, are inhibi-
tory in vivo, and the mTOR polypeptides that associate
with nucleotide-deficient Rheb in vivo lack kinase activ-
ity in vitro. Reciprocally, mTOR polypeptides bound to
Rheb(Gln64Leu), a mutant that is nearly 90% GTP
charged, exhibit substantially higher protein kinase
specific activity than mTOR bound to wild-type Rheb.
Conclusions: The TOR complex 1 is a direct target of
Rheb-GTP, whose binding enables activation of the
TOR kinase.
Introduction
Target of rapamycin (TOR) is a giant protein kinase that
regulates cell growth and proliferation in S. cerevisiae
as well as in metazoans [1, 2]. TOR functions in two
independent complexes. The TOR complex 1 (TORC1)
is comprised of TOR in association with the proteins*Correspondence: avruch@helix.mgh.harvard.edu
4These authors contributed equally to this work.raptor [3, 4] (KOG1 in S. cerevisiae [5]) and LST8 [5]
(also called GβL [6]), and its output is inhibited by rapa-
mycin. The TOR complex 2 (TORC2) contains TOR in
association with the proteins AVO3/rictor and LST8 [5,
7, 8]. TORC2 controls the actin cytoskeleton; its output
is insensitive to rapamycin and will not be considered
further here.
A major target of TORC1 regulation in all cells is
mRNA translation [9]. In mammalian cells, mTOR stimu-
lates translational initiation through the phosphoryla-
tion of 4E-BP1, an inhibitor of the binding of the mRNA-
cap binding protein eIF-4E to the eIF-4G scaffold.
Phosphorylation of 4E-BP1 promotes its dissociation
from eIF-4E, enabling recruitment of the latter into the
eIF-4F complex. mTOR also directly phosphorylates
and, in collaboration with PDK1, activates the p70 S6
kinase [10]; the latter regulates cell size [11] through
incompletely defined mechanisms. The ability of the
mTOR kinase to phosphorylate these targets is depen-
dent on the association of TOR with raptor, inasmuch
as raptor binds the TOR substrates 4E-BP1 and
p70S6K and presents them to mTOR [3]. In fact, the
ability of mTOR to phosphorylate 4E-BP1 is nearly elim-
inated by removal of raptor in vitro [3, 12], or in vivo by
mutation of the 4E-BP1 “TOS” motif [13], the 4E-BP1
segment that mediates binding to raptor [12, 14–16].
The ability of TOR to regulate p70S6K is also strongly
dependent on the association of p70S6K with raptor.
Mutation of the p70S6K TOS motif reduces mTOR-cat-
alyzed phosphorylation of p70S6K in vitro by approxi-
mately 75% and renders p70S6K insensitive to inhibi-
tion in vivo by rapamycin or to regulation by ambient
amino acids [12]. LST8, the third component of the
TORC1 complex [5, 6], is a 36 kDa polypeptide whose
predicted structure is composed entirely of seven WD
repeats, presumably arrayed in a so-called “β propel-
lor” [17]. LST8 plays an important but incompletely de-
fined role in TOR regulation. The polypeptide binds
tightly to the TOR catalytic domain and enhances the
association of raptor with mTOR [6]; however, other
roles remain likely.
In mammalian cells, mTOR output is sensitive to
amino-acid (especially leucine and arginine) sufficiency
but is also controlled by overall energy supply through
the AMP-activated protein kinase (AMPK) and by inputs
from cell surface receptors through the PI-3 Kinase
(PI3K)-PKB pathway [2]. Recent evidence indicates that
the tuberous sclerosis complex (a TSC1/TSC2 hetero-
dimer) acts as a negative regulator upstream of mTOR
and is a major target through which PKB, AMPK, and
perhaps amino-acid sufficiency control mTOR activity
[18–20]. Inactivation of TSC results in constitutive acti-
vation of p70S6K that is resistant to inhibition by with-
drawal of amino acids but sensitive to inhibition by
rapamycin [18, 20, 21]. PKB, whose overexpression in-
directly promotes the hyperphosphorylation of 4E-BP1
and activation of p70S6K, phosphorylates TSC2 at sev-
eral sites and may accelerate the degradation of both
TSC2 and TSC1, perhaps by promoting the dissociation
of the heterodimer [22–24]. In contrast, AMPK-cata-
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the TSC1/TSC2 complex to inhibit TOR [25].
The inhibition of TOR signaling by the TSC complex
is attributable to the ability of the TSC complex to act
as a specific GTPase-activating protein for the small
GTPase Rheb [26–31]; the latter is a positive regulator
of cell growth, which, in Drosophila, is epistatic to the
TSC complex but requires TOR to achieve growth stim-
ulation [32, 33]. The effectors utilized by Rheb to control
cell function are as yet unknown. Rheb is reported to
bind to the amino terminus of c-Raf1 and B-Raf [34,
35]. Nevertheless, Rheb does not activate Raf [35] and
inhibits cell transformation when coexpressed with
Ras(Gly12Val) [36].
The present studies were undertaken to elucidate the
mechanisms utilized by Rheb to control TOR signaling.
Our results demonstrate that Rheb regulation of mTOR
signaling occurs, at least in part, through the direct
binding of Rheb-GTP to mTOR, an interaction that pro-
motes activation of the mTOR kinase activity.
Results
Rheb Overexpression Rescues p70S6K from
Inactivation by Amino-Acid Withdrawal
Coexpression of p70 S6 kinase (p70S6K) with wild-type
Rheb in HEK293 cells stimulates the phosphorylation
of p70S6K (Thr412; this numbering refers to the 525
amino acid α1 isoform and is equivalent to Thr389 in
the 502 amino acid α2 isoform) and almost completely
overcomes the inhibitory effect of amino-acid with-
drawal (Figure 1A). The effect of Rheb is entirely abol-
ished by rapamycin, indicating a requirement for mTOR
(data not shown). Rheb expression has no significant
effect on the site-specific phosphorylation of the MAPK
activation loop or on PKB Ser473. By comparison, Ras-
(Gly12Val) strongly stimulates the activity of endoge-
nous MAPK but only slightly stimultes p70S6K Thr412
phosphorylation and doesn’t stimulate PKB Ser473 phos-
phorylation. Rap1b(Gly12Val) has little effect on any of
these protein kinases (Figure S1). These results support
the now widely held view that Rheb acts as a positive
regulator upstream of TOR and downstream of the TSC
complex [26, 27, 32, 33]; the latter functions as a Rheb
GTPase [26–31] and a negative regulator of TOR [19].
Effects of Rheb Mutations on Signaling
The effect of Rheb mutations on signaling to p70S6K
was examined. Rheb Ser20 corresponds to Ras Ser17,
whose replacement by Asn inactivates Ras and creates
a dominant inhibitory mutant [37]. Replacement of
Rheb Ser20 by Asn was shown previously to result in a
loss of function in S. pombe Rheb [38]. Transfected hu-
man Rheb(Ser20Asn) is expressed poorly as compared
with wild-type Rheb, and not surprisingly, this mutant is
unable to rescue p70S6K from amino-acid deprivation;
nevertheless, Rheb(Ser20Asn) causes a marked inhibi-
tion of p70S6K Thr412 phosphorylation in the presence
of serum and amino acids despite unaltered S6K ex-
pression (Figure 1A, compare lane 5 with lanes 1 and 3).
Mutations were introduced into three sites in the
Rheb switch 1 segment, Thr38Met (also shown to result
in loss of function of S. pombe Rheb [38]), Ile39Lys,and Asn41Ala. All three mutants are expressed at levels
comparable to wild-type Rheb. Both Thr38Met and
Ile39Lys lose the ability to stimulate p70S6K Thr412
phosphorylation in complete medium and to rescue
p70S6K Thr412 dephosphorylation induced by amino-
acid withdrawal (Figure 1A, lanes 1–4, 7, 8, and 11–16).
In addition, Ile39Lys expression causes inhibition of
p70S6K Thr412 phosphorylation in complete me-
dium (Figure 1A, compare lane 15 with lane 11). The
Asn41Ala mutant retains the ability to stimulate p70S6K
phosphorylation in complete medium but is greatly
compromised in its ability to rescue p70S6K from de-
phosphorylation induced by amino-acid withdrawal
(Figure 1A, lanes 1–4, 9, and 10).
The Rheb switch 2 mutant Asp60Ile was recently re-
ported to interfere selectively with GTP binding in vitro
[39]. This mutant is unable to rescue p70S6K from
amino-acid-withdrawal-induced dephosphorylation (Fig-
ure 1A, lanes 17, 18, 21, 22) and causes a moderate
inhibition of p70S6K Thr412 phosphorylation in com-
plete medium (Figure 1A, compare lane 21 with lane
17). Finally, we find that mutation of the Rheb prenyla-
tion site, Cys181Ser, reduces but does not eliminate the
ability of Rheb to rescue p70S6K from amino-acid de-
privation. The Cys181Ser mutant is still reasonably ef-
fective in stimulating p70S6K Thr412 phosphorylation
in complete medium (lanes 23–28).
The effects of wild-type and mutant Rheb on the
phosphorylation of 4E-BP1 in amino-acid replete and
deficient medium parallel those seen with p70S6K (Fig-
ure S2). Thus, the domains in Rheb concerned with
guanyl nucleotide binding and effector activation in the
TOR pathway are homologous to those defined for
other Ras-like GTPases.
Effects of Rheb Mutations on Guanyl
Nucleotide Binding
Wild-type and mutant Rheb were expressed transiently
as GST-fusion proteins in cells labeled with extracellu-
lar 32Pi (Figure 1B). Recovery of total Rheb-associated
32P-guanyl nucleotide increases in proportion to GST-
Rheb expression. At the lowest Rheb expression exam-
ined, i.e., at 32P levels bound to GST-Rheb that are only
two to four times greater than those recovered with
GST, the fraction of total Rheb bound nucleotide that is
32P-GTP varied from 42%–63%. This proportion stabi-
lized near 60% at higher levels of GST-Rheb polypep-
tide. Similar high levels of GTP charging have been re-
ported previously for recombinant Rheb [35, 40] and
have been attributed to saturation of endogenous
Rheb-GAP by the overexpressed Rheb polypeptide, to-
gether with the very low rate of intrinsic Rheb GTPase
activity.
The Rheb switch 1 mutants (Thr38Met and Ile39Lys)
exhibited %GTP similar to wild-type, whereas Rheb
(Cys181Ser) exhibited a slightly lower %GTP than wild-
type (Figure 1B). In contrast, no 32P-guanyl nucleotide
was recovered with Rheb(Ser20Asn) or (Asp60Ile), al-
though these mutants were expressed in amounts
comparable to those of wild-type Rheb. Therefore, the
steady-state binding of GTP + GDP in vivo to recombi-
nant Rheb(Ser20Asn) and (Asp60Ile) is less than 5%
that of wild-type Rheb and may be lacking completely.
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(A) The effect of wild-type and mutant Rheb on the phosphorylation in vivo of p70S6K in amino-acid-replete and -deficient medium. The
effect of wild-type and mutant Rheb on the phosphorylation in vivo of p70S6K in amino-acid-replete and -deficient medium. HEK293T cells
were transfected with pEBG-p70S6K (lanes 1–28) with pCMV5-FLAG vector (lanes 1, 2, 11, 12, 17, 18, 23, and 24) or with pCMV5-FLAG-Rheb
wild-type (lanes 3, 4, 13, 14, 25, and 26) or various mutants as indicated above each lane. 40 hr later, some plates were transferred to D-PBS
(lanes 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, and 28) and all cells were harvested 2 hr thereafter. Each panel represents a separate
experiment. The bar graph is a quantitation of the anti-Thr412-P immunoblot results for the experiments shown with the value of S6K
coexpressed with empty vector set to 100. A quantitative summary of the effect of recombinant Rheb on S6K(Thr412P) in replete medium as
a % of vector control is: Rheb(wild-type) (0.5 g/plate, n = 8; not including the experiment in lanes 23 and 25) = 194 ± 49 (= 1 SD)%;
Rheb(Asp60Ile) (2.8 g/plate, n = 3; 3.5 g, n = 1) 60 ± 16 (= 1 SD)%; Rheb(Ser20Asn), two experiments (0.5 g/plate) 40.6% and 59.6%.
(B) Guanyl nucleotide binding in vivo by wild-type and mutant Rheb. GST or GST fusions of wild-type or mutant Rheb were transiently
expressed in HEK293T cells in triplicate with 0.3 g of the pEBG vector, except for Ser20Asn (1.0 g) and Asp60Ile (1.0 or 2.0 g). 40 hr later,
the cells were washed and incubated in phosphate-free DMEM containing 0.2 mCi/ml of [32P] orthophosphate. After 4 hr, the GST and the
GST-fusion proteins were extracted and purified by GSH affinity chromatography and washed, and the bound guanyl nucleotides were
extracted and separated by thin layer chromatography as described in methods. 32P comigrating with GDP and GTP were quantified by
phosphoimager; the total [32P-GDP + GTP] (in arbitrary phosphoimager units) and the percentage of total [32P-GDP + GTP] as GTP are shown,
± one standard deviation. The GST immunoblot shows the relative amounts of purified GST proteins.We examined the ability of these Rheb mutants to bind R
iguanyl nucleotide in vitro, in comparison to wild-type
Rheb. The extent of γ35S-GTP binding in vitro by both B
aRheb(Ser20Ala) and (Asp60Ile) is less than 10% that of
wild-type Rheb, and their binding of 3H-GDP was near i
tbackground (data not shown). Thus the Ser20Asn and
Asp60Ile mutations markedly reduce and may eliminate e
RRheb binding of guanyl nucleotide.heb Binds Directly to the TOR Complex
n a Guanyl-Nucleotide-Independent Manner
iochemical and genetic evidence establish that the
bility of the TSC1/TSC2 heterodimer to act as an inhib-
tor of TOR signaling is mediated through Rheb. To test
he possibility that Rheb acts directly on mTOR, we first
xamined whether Rheb is capable of binding mTOR.
ecombinant GST or a variety of GST-Rheb fusion pro-
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the GSH isolate was probed for the presence of endog-
enous mTOR. As seen in Figures 2A and 2B, GST-Rheb
can coprecipitate endogenous mTOR (Figures 2A and
2B), as well as raptor (Figure 2A) and TSC2 (Figure 2B).
Notably, the inactive Rheb switch 1 mutant Thr38Met
binds endogenous mTOR in a manner equivalent to
wild-type GST-Rheb, whereas mTOR binding to Rheb
Ile39Lys and to GST-Rheb Gln64Leu is reduced as
compared to wild-type Rheb (Figure 2B). Surprisingly,
the nucleotide-free Rheb mutants Ser20Asn (Figure 2B)
and Asp60Ile (see below) also bind mTOR and retrieve
greater amounts of endogenous (Figure 2B) and recom-
binant mTOR (see below) than does wild-type Rheb. As
a specificity control, the GTPase-deficient forms of the
two most closely related small GTPases, GST-Ha-Ras
(Gly12Val) and GST-Rap1b(Gly12Val), bind much less
HA-mTOR than GST-Rheb in transient coexpression ex-
periments (Figure 2C).
We next sought to identify the region of mTOR re-
sponsible for binding Rheb. We coexpressed GST-Rheb
with a variety of FLAG-tagged fragments of mTOR. The
results are summarized in Figure 3A, and the data is
shown in Figure S3. No binding of Rheb to mTOR 1–670
and 1–1967 was observed; however, the mTOR frag-
ments 1967–2191, encompassing the FKBP12-rapa-
mycin binding domain, and 2148–2549, encompassingFigure 2. Recombinant Rheb Binds Specifically to Endogenous and Recombinant mTOR
(A) Recombinant Rheb binds to endogenous mTOR and raptor. HEK293T cells were transfected with pEBG (lane 1) or pEBG-Rheb wild-type
(lane 2). 40 hr later, cells were extracted, and the GST fusion proteins were purified on GSH-Sepharose. The GSH eluates and aliquots of the
extract were analyzed by immunoblot for mTOR (top two panels) and raptor (panels 3 and 4 from top). A Coomassie blue stain of the GSH
eluate is in the bottom panel.
(B) Coprecipitation of endogenous mTOR and TSC2 by recombinant wild-type or mutant Rheb. HEK293T cells were transfected with pEBG
(lanes 1 and 6) or pEBG-Rheb wild-type (lanes 2 and 7) or pEBG-Rheb mutants (Thr38Met, lane 3; Ile39Lys, lane 4; Gln64Leu, lane 5; Ser20Asn,
lane 8). The cells were processed as in Figure 2A. The GSH eluates and aliquots of the extract were analyzed by immunoblot for mTOR (top
two panels) and TSC2 (fourth and fifth panels from top). A Coomassie blue stain of the GSH eluate is shown in the bottom panel. The bar
graph in the third panel from top shows the ratio of endogenous mTOR recovered relative to GST-Rheb with the value for wild-type Rheb set
to 100.
(C) mTOR binds preferentially to Rheb as compared to Ras and Rap1b. HEK293T cells were transfected with pcDNA1-HA-mTOR with pEBG
(lane 1), pEBG-Rheb (lane 2), Ha-Ras(Gly12Val) (lane 3), or Rap1b(Gly12Val) (lane 4). 40 hr thereafter, some cells were harvested. The GST
fusion proteins purified on GSH-Sepharose were eluted and analyzed by anti-HA immunoblot (top) and Coomassie blue stain (bottom).the kinase catalytic domain to the protein carboxyter-
minus, each individually exhibit binding to GST-Rheb.
Further analysis shows that TOR 1967–2148 does not
bind Rheb, indicating that the aminoterminal margin of
the Rheb binding site is located between TOR 2148–
2191. Carboxyterminal truncation of the mTOR 2148–
2549 fragment shows that Rheb binding is unaffected
by deletion to mTOR amino acid 2300. The localization
of the Rheb binding site on mTOR to the segment be-
tween amino acids 2148–2300 achieved through tran-
sient coexpression was confirmed by in vitro binding
assays with purified GST-Rheb and immunopurified
FLAG-tagged mTOR fragments (Figure 3B).
The mTOR segment 2148–2300 encompasses the
aminoterminal portion of the mTOR catalytic domain
and overlaps the proposed ATP binding site (based on
homology to the PI3Kα), which includes the lysine at
mTOR amino acid 2187, which is universally conserved
in PI-3 kinases and PIKKs and the glycine-rich se-
quence GLIGW (mTOR amino acids 2235–2239). This
region of mTOR is highly conserved within the PI3K-
related protein kinase (PIKK) family [41]. We therefore
inquired whether Rheb can bind to other members of
this family, such as ATM or ATR. We were unable to
achieve matching levels of expression of full-length
mTOR, ATM, and ATR, so we compared the ability of
Rheb to bind to the homologous segments of these
Current Biology
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(A) GST-Rheb binding to mTOR fragments during transient expression. HEK293T cells were transfected with plasmids encoding FLAG-tagged
mTOR fragments and pEBG vector or pEBG-Rheb. 40 hr later, cells were harvested and lysates subjected to GSH-Sepharose affinity purifica-
tion. The eluates and cell lysates were analyzed by anti-FLAG immunoblot or by Coomassie blue stain. The recovery of the FLAG-tagged
mTOR fragments with GST-Rheb is indicated on the right as + or -. The immunoblot data supporting this summary is shown in Figure S3.
(B) GST-Rheb specifically binds purified mTOR 2148–2300 directly in vitro. The FLAG-tagged mTOR fragments 1967–2191, 1967–2147, 2148–
2549, and 2148–2300 were each expressed individually in HEK293T cells and eluted after immunopurification on immobilized anti-FLAG
monoclonal antibody. Aliquots of each FLAG-mTOR fragment were incubated in vitro with GSH-Sepharose-immobilized GST (lanes 3, 6, 9,
and 12) or GST-Rheb (lanes 2, 5, 8, and 11), both also purified after transient expression and charged in vitro with GMPPNP. After being
washed, the polypeptides retained on GSH-Sepharose were analyzed by anti-FLAG immunoblot (top) and Coomassie blue stain (bottom). An
aliquot representing 10% of the FLAG-polypeptide loaded with the GST proteins is shown in lanes 1, 4, 7, and 10.polypeptides, i.e., FLAG-tagged mTOR 2148–2549, ATM p
R2678–3056, and ATR 2288–2644. These PIKK segments
exhibited comparable binding to GST-Rheb (Figure 4A, t
wtop). In contrast, GST-Rheb does not bind to the cata-
lytic domains of several conventional protein kinases G
(Figure 4A, bottom). In summary, recombinant Rheb
binds to a 153 amino-acid segment of the mTOR poly- d
tpeptide that encompasses the ATP binding site of the
mTOR catalytic domain. Rheb exhibits comparable v
nbinding to this region of ATM and ATR but does not
bind to the catalytic domain of several subfamilies of p
2conventional protein kinases. The functional signifi-
cance of the Rheb binding to ATM/ATR is as not known t
Rand is under examination.
GST and the GST-Rheb fusion protein were also G
Fcoexpressed with FLAG-tagged versions of Raptor,
mLST8, TSC2, TSC1, and TSC2 together and a carboxy- v
cterminal fragment of TSC2 (1531–1807) encompassing
the GAP domain (Figure 4B). Specific binding of Rheb G
Rto LST8 and to the TSC2 carboxyterminal fragment is
consistently observed. Weak binding of recombinant f
aRheb to recombinant full-length raptor is usually de-
tectable, whereas Rheb binding to the carboxyterminal m
n(WD propellor) segment of Raptor is consistently ob-
served. Thus, recombinant Rheb is capable of specific A
2binding to the TOR complex at multiple sites.
We examined whether the ability of Rheb to bind to t
2the components of the mTOR complex is dependent on
Rheb GDP/GTP charging in in vitro binding assays. In c
wa preliminary experiment, immunopurified FLAG-Rheb
and FLAG-Ras(Gly12Val), charged with either GTPγS or a
(GDP, were incubated with GST-c-Raf1 50–150, a pro-
karyotic recombinant fusion protein encompassing the 1
bc-Raf1 “Ras binding domain” (RBD) [42, 43]. As ex-ected, the binding of Ras-GTP was much greater than
as-GDP. However, Rheb binding, although specific for
he presence of the Raf-RBD, was not only much
eaker than Ras but largely independent of whether
TP or GDP is bound (Figure S4).
Subsequent experiments indicated that, as observed
uring transient expression in vivo, the ability of Rheb
o bind to the components of the mTOR complex in
itro does not require the presence of any bound gua-
ine nucleotide (Figure 5). The ability of highly immuno-
urified FLAG-tagged versions of c-Raf1 1–257, mTOR
148–2549, hLST8, and Raptor 1009–1335 polypep-
ides to bind in vitro to mammalian recombinant GST-
heb, either nucleotide free or charged with GDP or
MPPNP, was examined (Figure 5). Each of these
LAG-tagged polypeptides could bind to GST-Rheb in
itro. Binding does not, however, require nucleotide
harging with either GTP or GDP. In fact, charging with
TP appears to substantially diminish the binding of
heb to mTOR 2148–2549 as well as to the c-Raf1 1–257
ragment, as compared to nucleotide-free Rheb. The
bility of nucleotide-free Rheb to bind in vitro to purified
TOR 2148–2549 is consistent with the ability of the
ucleotide-deficient Rheb mutants Ser20Asn and
sp60Ile to bind full-length mTOR and the mTOR 2148–
549 fragment in vivo more strongly than does wild-
ype Rheb. Moreover, the diminished binding of mTOR
148–2549 to GTP-charged Rheb as compared to nu-
leotide-free or GDP-charged Rheb is also consistent
ith the lesser ability of recombinant Rheb(Asn64Leu)
s compared to wild-type Rheb to bind endogenous
Figure 2B) and recombinant (see below) mTOR. TSC2
531–1807 fragment was used as a control in these
inding assays, as it contains the putative GAP domain
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(A) GST-Rheb binds to homologous regions of the catalytic domains of the PIKKs, mTOR, ATM, and ATR but not to the catalytic domains of
several subfamilies of conventional protein kinases. In the experiment shown in the upper panels, pEBG or pEBG-Rheb was coexpressed
with plasmids encoding FLAG-tagged mTOR 2148–2549 (lanes 1 and 2), ATR 2288–2644 (lanes 3 and 4), or ATM 2678–3056 (lanes 5 and 6).
A second experiment is shown in the lower panels in which pEBG or pEBG-Rheb was coexpressed with plasmids encoding FLAG-tagged
mTOR 2148–2549 (lanes 7 and 8), MST1 1–326 (lanes 9 and 10), Nek6 (lanes 11 and 12), or p70S6KCT104 (lanes 13 and 14). The affinity-
purified GST fusion proteins were eluted with GSH and examined by anti-FLAG immunoblot and Coomassie blue stain. An anti-FLAG immu-
noblot of the cell lysates is also shown (middle).
(B) GST-Rheb binds to LST8, the raptor carboxyterminal WD domain, and the TSC2 GAP domain. HEK293T cells were transfected with pEBG
(not shown) or pEBG-Rheb and plasmids encoding p70S6K, mTOR complex components, or fragments thereof (as indicated above each
lane). 40 hr later, the cells were harvested, and GST-Rheb was processed as in Figure 3A. No FLAG immunoreactivity coprecipitated with
GST (not shown).for Rheb. The TSC2 GAP domain bound GMPPNP-
charged Rheb much better than GDP-charged Rheb.
Surprisingly, TSC2 GAP domain also bound nucleotide-
free Rheb as well as GMPPNP-charged Rheb.
Rheb Regulates TOR Kinase Activity
The ability of Rheb to bind directly to mTOR impelled
us to examine whether Rheb directly regulates mTOR
kinase activity assayed in vitro. Direct addition in vitroof an excess of mammalian recombinant GST-Rheb,
charged with GTP or GDP, does not alter the kinase
activity of HA-mTOR, in comparison to the addition of a
comparable amount of GST (data not shown). Although
difficult to assess quantitatively, the efficiency with
which recombinant Rheb associates with HA-mTOR in
vivo or in vitro appears to be low. We therefore exam-
ined specifically the kinase activity of mTOR polypep-
tides that are bound to recombinant Rheb. Wild-type
Current Biology
708Figure 5. The Effect of Guanyl Nucleotide on Rheb Binding In Vitro to the c-Raf1 Ras Binding Domain, the mTOR Catalytic Domain, LST8, the
Raptor WD Domain, and the TSC2 GAP Domain
GST-Rheb, purified on GSH-Sepharose after transient expression in HEK293 cells, was either stripped of endogenous nucleotide with EDTA
and washed in nucleotide-free buffer or charged in vitro with GDP or GMPPNP. Recombinant GST was treated in parallel. Each species of
GST or GST-Rheb was incubated with immunoaffinity-purified, soluble FLAG-tagged polypeptides: c-Raf1 1–257 (lanes 2–7), mTOR 2148–
2549 (lanes 9–14), LST8 (lanes 16–21), raptor 1009–1335 (lanes 23–28), or TSC2 1531–1807 (lanes 30–35). After being washed, the adsorbed
polypeptides were subjected to SDS-PAGE and analyzed by anti-FLAG immunoblot and Coomassie blue stain. Lanes 1, 8, 15, 22, and 29
contain 10% of the amount of FLAG-polypeptide added into the binding reaction.Rheb expressed singly, when purified, exhibits a slight R
Wprotein kinase activity toward p70S6K/4E-BP1 in vitro,
presumably because of a copurifying kinase. Coexpres- G
Rsion of Rheb with wild-type HA-mTOR markedly in-
creases the kinase activity recovered with Rheb (Figure i
a6A), whereas the kinase activity associated with GST-
Rheb coexpressed with kinase-dead HA-mTOR(Asn- c
t2343Lys) [44] is very low and similar to that coprecip-
itating with GST (Figure 6A, right). Moreover, the Rheb- n
iassociated kinase activity directed specifically toward
p70S6K Thr412 is increased by coexpression with wild- I
mtype HA-mTOR to an even greater extent than is the
overall Rheb-catalyzed 32P transfer to p70S6K (Figure 4
T6A). Thus, the Rheb-associated p70S6K Thr412 kinase
activity is attributable to mTOR. b
tHA-TOR bound to nucleotide-deficient mutants ofheb is essentially devoid of kinase activity (Figure 6B).
ild-type HA-mTOR was coexpressed with wild-type
ST-Rheb or with the inactive Rheb mutants, GST-
heb(Ser20Asn) or (Asp60Ile) and the TOR kinase activ-
ty recovered with the GSH-Sepharose isolates was
ssayed. Inasmuch as greater amounts of HA-mTOR
oprecipitate with the nucleotide-deficient Rheb mu-
ants than with wild-type Rheb, we used the HA immu-
oblot to equalize the amount of HA-mTOR introduced
nto the kinase assays (Figure 6B, bottom two panels).
t is evident that the HA-TOR coprecipitating with the
utant, inactive Rheb exhibits little or no p70S6K- and
E-BP1-kinase activity (Figure 6B, panels 2–4 from top).
hus, although the nucleotide-deficient Rheb mutants
ind HA-mTOR more tightly than does wild-type Rheb,
he HA-mTOR polypeptides bound to these mutants
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(A) Coexpression of wild-type but not kinase-dead mTOR with GST-Rheb increases the in vitro Rheb-associated kinase activity toward
p70S6K and 4E-BP. Left, GST-Rheb expressed alone (lane 2) or with HA-mTOR (lane 1) was purified on GSH-Sepharose and equal amounts
of GST-Rheb polypeptide (second panel from top) were assayed for kinase activity (lowest three panels) toward a recombinant p70S6(355–
525) polypeptide (third panel from bottom). Substrate phosphorylation in vitro was estimated by overall incorporation of 32P (second panel
from bottom) and by anti-p70S6K(Thr412P) immunoblot (bottom). Right, the kinase activity associated with GST (lane 1) or GST-Rheb (lanes
2 and 3) expressed with wild-type HA-mTOR (lane 2) was compared to GST-Rheb expressed with the kinase-inactive mTOR mutant
(Asn2343Lys) (lane 3) in assays equalized for identical amounts of mTOR polypeptide (top). The phosphorylation of p70S6K 355–525 (middle
three panels) and 4E-BP1 (lowest three panels) was analyzed by overall incorporation of 32P (second and fourth panels from bottom) and by
immunoblot against p70S6K(Thr421P) (fourth panel from bottom) and 4E-BP1(Thr37P, Thr46P), respectively. Each experiment was repeated
twice with nearly identical results.
(B) mTOR bound to guanyl nucleotide-deficient Rheb mutants exhibits little or no protein kinase activity. HA-mTOR was expressed with GST
(lane 2) or with GST fusions to Rheb wild-type (lane 3), Rheb(Ser20Asn) (lane 4), or Rheb(Asp60Ile) (lane 5). After purification on GSH-
Sepharose, the bound proteins were eluted, and aliquots containing equal amounts of HA-mTOR polypeptide (second panel from bottom)
were assayed for kinase activity toward p70S6K(355–525) (lanes 1–5) and 4E-BP1 (lanes 6–10). Substrate phosphorylation was estimated by
overall 32P incorporation, displayed both by a representative autoradiograph (fifth panel from bottom) and quantitatively by phosphoimager
(fourth panel from bottom). The bar graphs display the combined results from three experiments, as a percentage (± 1 SD) of the mTOR
kinase activity, set to 100, associated with wild-type Rheb. Representative immunoblots with anti-p70S6K(Thr412P) (third panel from bottom,
lanes 1–5) and anti-4E-BP1(Thr37P, Thr46P) (third panel from bottom, lanes 6–10) antibodies are shown.are unable to acquire kinase activity during transient
expression. Reciprocally, we examined the protein ki-
nase activity of HA-mTOR polypeptides bound to GST-
Rheb(Gln64Leu) as compared to wild-type Rheb (Figure
7). Overexpressed recombinant Rheb(Gln64Leu) is re-
ported to be approximately 90% GTP charged as com-
pared to the 50% GTP charging observed for wild-type
Rheb expressed in parallel at comparable levels [40].
Somewhat lesser amounts of HA-mTOR polypeptide
are recovered with GST-Rheb(Gln64Leu) as compared
with wild-type GST-Rheb (Figure 7B); however, when
comparable amounts of Rheb bound HA-mTOR poly-
peptide are assayed for kinase activity in vitro (Figures
7C and 7D), the HA-mTOR bound to GST-Rheb(Gln64Leu)
exhibits substantially higher p70S6K Thr412 kinase ac-
tivity than that bound to wild-type GST-Rheb. We infer
that HA-mTORs bound to wild-type Rheb reflect a mix-
ture of HA-mTORs bound to Rheb-GTP, which have
high kinase activity, and (given the 40%–50% GDPcharging we observe for wild-type Rheb) a comparable
amount of HA-mTOR bound to Rheb-GDP, which we
presume to have lower kinase activity. We are unable
to demonstrate the latter point directly, inasmuch as we
have not identified a Rheb mutant that is locked into
the GDP bound form. Nevertheless, the ability of the
Rheb-GAP, TSC1/TSC2, to inhibit mTOR signaling in
vivo is consistent with the inference that Rheb-GDP
provides a less effective stimulus than Rheb-GTP.
Finally, we examined the kinase activity of the small
amounts of HA-mTOR that associate with coexpressed
GST-Ha-Ras(Gly12Val) and GST-Rap1b(Gly12Val), in com-
parison to that associated with GST-Rheb and GST-
Rheb(Asp60Ile) (Figure S5). When compared at equal
HA-mTOR polypeptide levels, the p70S6K Thr412 ki-
nase activity associated with GST-Ha-Ras(Gly12Val) is
very low and similar to that recovered with GST-Rheb-
(Asp60Ile), whereas the p70S6K Thr412 kinase activity
associated with GST-Rap1b(Gly12Val) is about 50%
Current Biology
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Has Higher Kinase Activity than mTOR
Bound to Wild-Type Rheb
(A) Immunoblots of lysates from cells coex-
pressing HA-mTOR with GST or with GST fu-
sions to Rheb wild-type, Rheb(Gln64Leu), or
Rheb(Asp60Ile).
(B) Immunoblots of the GST proteins and co-
purifying HA-mTOR polypeptides after purifi-
cation on GSH-Sepharose. Lanes 1–12 dem-
onstrate the GST polypeptides as 4×, 2×,
and 1× aliquots (bottom) and associated HA-
mTOR (top).
(C) A repesentative kinase assay of the GST
bound HA-mTOR polypeptides. After elution
with GSH, aliquots containing equal amounts
of HA-mTOR polypeptide, as shown by
immunoblot (top) were assayed for kinase
activity toward p70S6K(355–525) (third
panel from top). Substrate phosphorylation
was estimated by immunoblot with anti-
p70S6K(Thr412P) (bottom).
(D) A summary of three mTOR kinase assays.
The bar graph shows results from two exper-
iments. The results are expressed as in Fig-
ure 6B.that associated with GST-Rheb. Thus, in addition to t
ttheir very much weaker ability than Rheb to bind mTOR,
Rap1(Gly12Val) and especially Ras(Gly12Val) exhibit f
pmuch less ability to support the activation of bound
mTOR polypeptides than does wild-type Rheb. c
d
cDiscussion
R
mThe primary aim of the present experiments was to de-
stermine whether Rheb interacts with the TOR complex
dand whether such an interaction has a positive regula-
5tory effect; the results provide affirmative answers to
rthese two questions. Thus, mTOR is a direct target and
Tan “effector” of the Rheb GTPase. The major difference
cbetween the mode of action of Ras [45] and that pro-
sposed here for Rheb is that in the case of Ras, GTP
icharging is necessary for the ability of Ras both to bind
tand activate its effectors, whereas Rheb GTP charging
dis necessary only for effector activation. Rheb binding
3to its putative effector mTOR does not require Rheb
wguanyl nucleotide charging.
GRecombinant Rheb binds to the mTOR catalytic do-
omain specifically, in the sense that other small GTPases
hmost closely related to Rheb (i.e., Ras and Rap1) ex-
qhibit much weaker binding to mTOR. Moreover, al-
othough Rheb binds to the catalytic domains of other
PIKKs such as ATM and ATR, Rheb does not bind to
eany of the several conventional protein kinase domains
oexamined. Surprisingly, the ability of Rheb to bind
amTOR does not require Rheb nucleotide charging; in
fact, nucleotide-free Rheb binds to mTOR more tightly ehan does Rheb-GTP, both in vivo and in vitro. Never-
heless, the relevance of Rheb-GTP binding to mTOR
unction is demonstrated by the finding that the mTOR
olypeptides that bind in vivo to the nucleotide-defi-
ient Rheb mutants (Ser20Asn or Asp60Ile) are greatly
eficient in protein kinase activity assayed in vitro. Re-
iprocally, mTOR polypeptides bound to recombinant
heb(Gln64Leu), a mutant reported to be approxi-
ately 90% GTP charged in vivo [40], exhibit a sub-
tantially higher kinase specific activity in vitro than
oes mTOR bound to wild-type Rheb, which is only
0%–60% GTP charged. These results establish the
egulatory significance of the Rheb-TOR interaction.
he association of mTOR with GTP-charged Rheb in-
reases mTOR kinase activity. Conversely, if mTOR as-
ociates with a nucleotide-deficient Rheb polypeptide
n vivo, the mTOR is trapped in a kinase-inactive form
hat is unable to phosphorylate in vitro both raptor-
ependent (4E-BP1) and raptor-independent (p70S6K
55–525 fragment) substrates. Based on these results,
e propose that the association of mTOR with Rheb-
TP is a necessary step in the physiologic activation
f the mTOR kinase. The present data do not establish
owever whether the mTOR kinase, once activated, re-
uires an association of Rheb-GTP for the maintanence
f mTOR kinase activity.
How Rheb-GTP functions within the TOR complex to
nable the acquisition of mTOR kinase activity and to
vercome the inhibition of TOR signaling caused by
mino-acid withdrawal is not yet known. The effort to
lucidate the site(s) at which amino-acid deficiency in-
Rheb Binds and Regulates the mTOR Kinase
711terrupts mTOR signaling and the mechanism of rescue
by recombinant Rheb are impeded by the inability as
yet to fully reconstitute this regulatory behavior in vitro.
Thus, despite their dramatic effects in vivo, neither
amino-acid withdrawal [46] or coexpressed recombi-
nant wild-type Rheb, singly or together, alter mTOR ki-
nase activity assayed in vitro (data not shown). This be-
havior suggests that the effect(s) of amino-acid removal
and recombinant Rheb on mTOR are poorly retained on
cell disruption and may not be due to stable alterations
in any of the components of the TOR complex. Alterna-
tively, the conditions used for mTOR kinase assay in
vitro may obscure the functional impact of alterations in
the TOR complex. We find that amino-acid withdrawal
inhibits the binding of Rheb to mTOR (X.L., S.O.-V., Y.L.,
and J.A., unpublished data). If the association of en-
dogenous Rheb with mTOR is required for the mainte-
nance as well as for the initiation of TOR kinase activa-
tion, then the ability of amino-acid withdrawal to inhibit
the Rheb-mTOR interaction may be responsible in part
for the concomitant inhibition of mTOR signaling. If,
however, the Rheb-mTOR interaction is only necessary
for the initiation of mTOR kinase activation, then some
additional site of Rheb action is required, within the
TOR complex or elsewhere, to explain both the pro-
gressive and ultimately complete inhibition of TOR sig-
naling that occurs in the first 2 hr after withdrawal of
amino acids as well as Rheb’s ability to overcome the
inhibitory effect of amino-acid withdrawal.
Any proposal for the mechanism by which amino
acids regulate TOR signaling must explain why muta-
tions of the p70S6K TOS motif that eliminate p70S6K
binding to raptor [12], although they reduce p70S6K
phosphorylation in vivo at Thr412 (the dominant site of
mTOR-catalyzed p70S6K phosphorylation), also render
this phosphorylation insensitive to amino-acid with-
drawal [46]. This behavior suggests that amino-acid de-
ficiency, rather than impairing mTOR catalytic activity
per se, interferes with the ability of raptor to present
substrates to mTOR, perhaps, for example, by altering
raptor binding to either mTOR or to p70S6K/4E-BP1.
We have not observed effects of amino-acid withdrawal
on p70S6K or 4E-BP1 association with raptor (data not
shown). Moreover, Kim et al. [4] reported that amino-
acid withdrawal actually increases raptor association
with mTOR. Nor have we observed any effect of coex-
pressed Rheb on the binding of raptor to either mTOR
or to p70S6K/4E-BP1 in the presence or absence of
amino acids (data not shown). Nevertheless, the possi-
bility remains that overexpressed Rheb-GTP is able
to restore effective coupling between raptor and
mTOR, perhaps mediated by Rheb’s multiple interac-
tions within the TOR complex.
In summary, the current data support the following
model for the role of Rheb in the activation of the mTOR
kinase: Rheb binds to the TOR catalytic domain and
independently to LST8, which also binds nearby to the
TOR catalytic domain [6]; Rheb also shows a weak in-
teraction with the raptor carboxyterminal WD domains.
Rheb binding to these elements does not require Rheb
guanyl nucleotide charging. Nevertheless, the data
shown in Figure 5 indicate that the binding of TOR to a
nucleotide-free Rheb does not activate but rather im-
pedes TOR kinase activation, whereas binding to Rheb-GTP is accompanied by a high kinase activity. Thus, we
propose that association of a wild-type, GTP-charged
Rheb with the TOR complex is necessary to initiate the
transformation of the complex into a configuration
competent to catalyze phosphorylation of physiologic
substrates. As with other Ras-like GTPases, binding
GTP restructures the Rheb switch 1, switch 2 and per-
haps other Rheb segments. Although Rheb GTP charg-
ing weakens the association of Rheb with the mTOR
catalytic domain, the configuration of GTP-charged
Rheb enables the TOR complex to adopt a form that
is both catalytically active and capable of productive
signaling in vivo. Once mTOR is activated, the current
evidence does not specify whether a continued associ-
ation of Rheb-GTP is required for the maintanence of
an active configuration of TORC1. Rheb-GTP may re-
main loosely associated with the complex, in which
case alterations in the activity of the TOR-associated
TSC complex may be critical in the regulation of TOR
kinase activity. Alternatively, Rheb-GTP may be con-
cerned primarily with the initiation of TOR activation,
and subsequent alterations in TORC1 may be neces-
sary to maintain the active state. In either case, the fact
that physiologic regulation of the TSC complex (a
Rheb-GAP) is reflected relatively quickly by alterations
in mTOR signaling suggests that mTOR kinase activity
is in a state of continuous turnover in amino-acid-
replete cells. The ability of overexpressed Rheb to res-
cue TOR signaling from amino-acid withdrawal may be
attributable to the ability of Rheb-GTP to promote
mTOR kinase activity (as shown herein) and perhaps
also the coupling between mTOR and raptor; however,
direct evidence for the latter action remains to be
established.
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